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Correlations of baseline physiotherapy tests and one year with the values the
function scales
Correlations WOMAC WOMAC
Pain
VAS LEQUESNE SF36
PCS
SF36
MCS
TUG Baseline r 0.263 0.209 0.230 0.294 0.243 0.223
p <0.001 0.005 0.002 <0.001 0.001 0.002
N 182 182 182 182 182 182
TUG 1 Year r 0.313 0.260 0.274 0.383 0.267 0.273
p <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
N 182 182 182 182 182 182
FtSST Baseline r 0.325 0.239 0.245 0.299 0.333 0.168
p <0.001 0.001 0.001 <0.001 <0.001 0.023
N 182 182 182 182 182 182
FtSST 1 Year r 0.294 0.276 0.177 0.247 0.280 0.156
p <0.001 <0.001 0.017 0.001 <0.001 0.036
N 182 182 182 182 182 182
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DOES YOGA IMPROVE PAIN, STIFFNESS AND PHYSICAL DISABILITY IN
KNEE OSTEOARTHRITIS? e A RANDOMIZE CONTROLLED CLINICAL
TRIAL
R.N. Srivastava, V. Avasthi, S.R. Srivastava, S. Raj. KG Med. Univ., Lucknow,
India
Purpose: Osteoarthritis (OA) is a common problem in old age that is
associated with pain and disabilities. Primarily it was considered as a
degenerative disease but recently evidences are emerging about
inﬂammation as a causative factor. Several non-pharmacological
interventions are effective in reducing the inﬂammation as well as
relieving the symptoms of OA. Yoga is a physical, mental and spiritual
discipline to improve one’s inherent power of healing in a balanced
manner. Health is balance of mind, body and spirit and yoga means to
join or “yoke” together the mind, body and spirit. Effects of yoga
practices inﬂuence the sympathetic and parasympathetic activity in the
autonomic nervous system. Chakras or plexii are the psychic centres of
the body through which energy ﬂows. Each chakra or center controls a
particular area and particular glands. Asanas are physical postures,
which stretch and strengthen different parts of the body, massaging and
bringing fresh blood to the internal organs while rejuvenating the
nervous system and lubricating the joints, muscles, and ligaments. Each
asana is purported to have different effects on the nervous and circu-
latory systems, coordination and concentration and calming effect on
the body. There is limited evidence documenting its effectiveness in
management of osteoarthritis. This study was conducted to determine
the role of Yoga on pain, stiffness and physical disability in knee
osteoarthritis (KOA) by WOMAC scores and to determine the role of
Yoga on inﬂammatory markers Interleukin 6 (IL-6) and Interleukin 10
(IL-10) in subjects of KOA.
Methods: One hundred and twenty patients of OA knee were
randomized into two groups based on computer generated random
table - Gp A as cases and Gp B as controls. GpA subjects were kept on
conventional treatment along with add-on integrated supervised yoga
of 45 min duration of 5 Asanas (Virbhadra, Suptata, Uttanapa, Dand
and Paschimotsav). Gp B subjects were kept on conventional treat-
ment alone. Conventional treatment was in form of Quadriceps drill
exercises, hot saline fomentation, parafﬁn wax bath and analgesic
drug. Patients were assessed at baseline and at 6-month interval by
measurement of inﬂammatory biomarkers Interleukin 6 (IL-6), Inter-
leukin 10 (IL-10), and WOMAC score for clinical parameters of severity
of OA knee before in both cases and controls. Equal number of subjects
in both the groups was recruited from the OPD of the Department of
Orthopedic Surgery, following American College of Rheumatology
(ACR) criteria for KOA. These were proﬁled for demographic, clinical
(WOMAC Scores) and radiological features. Assessment of means was
compared. The selected interleukins were analyzed at 1st visit and at
6th month. Biochemical examination had been done quantitatively by
ELISA technique.
Results: The statistical analysis was done using statistical analysis
software SPSS Version 15.0. The values were represented in Number
(%) and Mean±SD. Wilcoxon signed rank test was used to evaluate the
within group change. Statistically signiﬁcant fall in IL-6 and improved
IL-10 level was found in the intervention group GpA. Further, there
was a signiﬁcant reduction in doses of analgesic drugs, being given to
patients of Gp A. Inﬂammation level rose signiﬁcantly in those
patients who left practicing yoga. Thus, with use of yoga therapy,
requirement of analgesic drugs may be signiﬁcantly decreased and in
some cases may be withdrawn altogether in KOA patients. There was
a decrease in WOMAC scores for stiffness and pain and increase in
social function score, which was statistically insigniﬁcant. WOMAC
score for emotional function decreased signiﬁcantly. The total
WOMAC score decreased signiﬁcantly in GpA. In Gp B there was a
decrease in IL6, stiffness, pain and emotional function scores but this
difference was not statistically signiﬁcant, no signiﬁcant increase in
social function score whereas physical function score increased and
was statistically signiﬁcant. Total WOMAC score was decreased but
was statistically insigniﬁcant.
Conclusions: The results indicate that add on intensive supervised yoga
therapy in knee osteoarthritis patients can help to improve inﬂamma-
tory biomarkers, physical functions and quality of life. Yoga can serve as
an adjuvant with existing conventional treatment of OA knee and
prolong add-on yoga can even augment certain pathophysiological
processes involved in the progression of disease.253
ANALYSIS AND CORRELATION OF PHYSICAL THERAPY TESTS, PAIN,
FUNCTION AND QUALITY OF LIFE QUESTIONNAIRES IN PATIENTS
FROM PARQVE (PROJECT ARHTRITIS RECOVERING QUALITY OF LIFE
BY MEANS OF EDUCATION)
F.E. Farias, C.A. Silva, C.H. Cernigoy, M.U. Rezende. Inst. de Ortopedia e
Traumatologia do Hosp. das Clinicas da Faculdade Med. da Uiversidade
de S~ao Paulo, Sao Paulo, Brazil
Purpose: To evaluate the effects of a multi-professional educational and
assistance program to patients with knee ostearthritis (KOA) by means
physical tests and questionnaires and correlate results obtained.
Methods:One hundred and ninety-eight patients in usual treatment for
KOA were randomized to 4 groups. All groups received a booklet and a
DVD with information regarding KOA (causes and treatment modal-
ities). Three groups also attended two days of lectures 1,2 and 3 months
apart. All groups were divided in subgroups A (bimonthly telephone
calls) and B (no telephone calls). All patients were evaluated at baseline
and at one year with Timed up and go (TUG) and ﬁve times sit to stand
test (FTSST), and asked to answer WOMAC, LEQUESNE, VAS and SF-36
scores.
Results: The FTSST improved in average 4.66 seconds (CI 3.95, 5.36)
regardless of the group or telephone calls (p 0 and p 0 and p <0.05)
(Table). No correlation was found between improvements in the FTSST
or TUG and any of the changes of the questionnaires.
Conclusions: The multi-professional treatment improved strength of
KOA patients as measured by FTSST. This improvement does not cor-
relate with improvements in pain, function and quality of life ques-
tionnaires (WOMAC, WOMAC pain, VAS, LEQUESNE and SF-36).254
EFFECT OF LOW-LEVEL LASER THERAPY (904 NM) AND STATIC
STRETCHING EXERCISES IN PATIENTS WITH KNEE
OSTEOARTHRITIS: A RANDOMISED CONTROLLED TRIAL
S.F. Meneses y,z, D.J. Hunter y, A.P. Marques z. yRoyal North Shore Hosp.,
Rheumatology Dept., and Inst. of Bone and Joint Res., Kolling Inst., Univ.
of Sydney, Sydney, Australia; zUniv. of Sao Paulo, Sao Paulo, Brazil
Purpose: The effect of low-level laser therapy (LLLT) and static
stretching exercises for knee osteoarthritis (OA) symptoms is unknown.
This randomised controlled trial aimed to investigate the effect of these
two interventions, as monotherapy and in combination, on pain, self-
reported symptoms, function, mobility, knee range of motion (KROM)
and hamstring length in participants with knee osteoarthritis (KOA).
Methods: One hundred and forty ﬁve people aged 50-75 years with
symptomatic radiographic KOA were recruited from the community
and randomly allocated to ﬁve study groups (n¼29 each): LLLTACTIVEþ
Stretch, LLLTPLACEBO þ Stretch, Stretch, LLLT and Control. LLLT con-
sisted of 9 sessions in the combined treatment groups (LLLT þ
stretching) and 24 sessions when used as monotherapy. The device
used was a Galium-Arsenide laser (904nm, 40mW, 3J/point, 27J/knee).
Stretching consisted of 7 different exercises repeated for 24 sessions.
Treatment frequency was 3x/week. The control group received a
booklet. Participants and assessor were blind to treatment allocation.
Measurements were taken at baseline and after each intervention. The
primary outcome was pain measured by Visual Analogue Scale. Sec-
ondary outcomes included self-reported symptoms assessed by
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function by Lequesne Algofunctional Index, mobility by Timed Up and
Go Test (TUG), KROM by goniometry of knee ﬂexion and hamstring
shortening by popliteal angle. The statistical method followed the
principles of per-protocol analysis.
Results: On average, the participants’ age was 63.5 years, the BMI was
31.2 and 78.4% were women. All groups demonstrated a signiﬁcant
improvement in pain, total WOMAC, Lequesne and TUG following
treatment compared to control (both p<.001). Hamstring shortening
improved after the combined treatment (LLLT þ stretching) (p<.001).
The LLLTPLACEBO þ Stretch was the only group better than control in
improving KROM (p¼0.02). On average, there was a 50% improve-
ment in pain, 39% in total WOMAC, 30% in Lequesne and 20% in TUG
for all active treatment groups compared to a control. For the com-
bined treatment groups there was a 43% improvement in hamstring
length.
Conclusions: Our results suggest that LLLT and static stretching, com-
bined or as monotherapy, were effective in reducing pain and improv-
ing self-reported symptoms, mobility and function. Only the combined
treatment demonstrated improvements in hamstring shortening.Initial Assessment x Final Assessment
Groups Average gain Relative
gain
p
Average ± SD/ Median
[25%-75%]
VAS (0e10 cm) 1 3.2 ± 2.1 50.3% <0.001
2 3.8 ± 2.3 57.7%
3 3.1 ± 2.9 47.0%
4 3.3 ± 2.2 54.2%
5 0.7 ± 3.0 12.4%
WOMAC (0e96) 1 8.0 [6.0  15.0] 33.9% <0.001
2 11.0 [4.5  21.5] 38.9%
3 13.0 [5.7  22.5] 42.0%
4 16.0 [8.7  24.5] 41.4%
5 2.0 [ 2.5  8.5] 1.5%
LEQUESNE (0e24) 1 2.5 [0.4  5.1] 23.4% <0.001
2 1.5 [0.5  5.2] 25.8%
3 4.0 [0.5  6.6] 39.6%
4 3.5 [1.9  5.6] 31.5%
5 0.0 [2.2  1.0] -10.4%
TUG(s) 1 2.5 [0.2  4.7] 18.0% <0.001
2 3.0 [1.1  6.7] 23.1%
3 2.6 [1.3  4.1] 19.1%
4 3.1 [0.5  6.4] 19.9%
5 0.0 [1.0  1.2] -1.3%
KROM () 1 7.0 [3.0  15.0] 9.4% 0.02
2 10.0 [4.0  15.2] 12.0%
3 6.0 [1.0  11.5] 5.3%
4 10.0 [7.5  23.2] 8.5%
5 1.0 [5.5  7.0] 0.9%
Popliteal angle () 1 10.0 [1.0  15.0] 37.6% <0.001
2 12.0 [5.0  18.2] 47.9%
3 4.0 [1.2  8.7] 11.7%
4 0.0 [6.0  6.2] 1.2%
5 0.5 [4.5  4.0] 1.2%255
THE CURRENT STATUS OF IMAGING IN ANTI-NGF CLINICAL TRIALS
C.G. Miller y, A. Guermazi z, H. Yu y, F. Roemer x. yBioClinica, Newtown,
PA, USA; zBoston Univ. Sch. of Med., Boston, MA, USA; xUniv. of
Erlangen-Nuremberg, Erlangen, Germany
Purpose: Nerve Growth Factor (NGF) is a neurotrophin that regulates
the structure and function of responsive sensory neurons and is a
regulator of pain sensitivity and processing. The concept of targeting
NGF to target chronic pain syndromes has been gaining momentum
since 1990.
There have been a signiﬁcant number of trials conducted or being ini-
tiated. This abstract provides a review of the studies that have evaluated
a-NGF compounds.Methods: A thorough review was performed on the web site www.
clinicaltrials.gov to identify all a-NGF studies that have been con-
ducted. The terms anti-NGF, and a-NGF only return a limited number
of results so the individual compounds had to be identiﬁed either by
their generic name or compound number. 45 studies were identiﬁed
and although 2 studies had been withdrawn prior to randomization, a
total of 15,664 subjects have been enrolled in studies with the aNGF
mAbs. Seven of these trials have been published in peer-reviewed
journals.
Results: While the majority (26) of studies have been conducted by
Pﬁzer with Tanezumab, there have been 7 with Fulranumab previously
known as JNJ-42160443 (Johnson & Johnson Pharmaceutical Research
& Development), and 9 with Fasinumab previously known as REGN475
(Regeneron pharmaceuticals/Sanoﬁ). Many of the studies have been
either terminated (24), or completed (16) but there is one currently
active (not recruiting) in cancer-related pain (Fulranumab). There is also
a study of 450 subjects with OA of the knee and hips that is planned to
start recruiting in January 2014.
The number of indications that have been studied comprise of osteo-
arthritis (21), which includes either the knee, hip or both; low back pain
(4), and a variety of pain syndromes (11) including neuropathic pain
from diabetes (2), plus three in cancer pain of which one is on-going.
In the Tanezumab program 249 subjects were adjudicated for AEs
related to the joints. Of these 68 had Rapidly Progressing Osteoarthritis
(RPOA), 67 in the Phase III program and 1 in the Phase 1 program for
chronic back pain. The advisory board noted that 13 of the 68 subjects
had deﬁnite evidence of SIF at enrollment. This program had the largest
number of enrolled subjects at the time of FDA cessation of the program
(13310 subjects of the 15,664 enrolled in aNGF studies or 85%). While
these subjects were identiﬁed post hoc, SIF, RPOA and joint destruction
was not an AE that was anticipated a priori and therefore nothing pro-
actively built into the studies to evaluate the true incidence of these
events.
Conclusions: In summary, medical imaging and the thorough radio-
logical evaluation of the major articulating joints for all subjects in
future aNGF studies will be required. The ﬁrst step will be to rule out
possible pathology or those at high risk of going onto a catastrophic
joint failure. Then secondly to closely monitor the subjects during the
treatment phase with radiography and if inconclusive also with mag-
netic resonance imaging to ensure that any possible events will be
identiﬁed early and the subject managed to prevent any further bone or
joint damage.
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RADIOGRAPHIC AND MRI ASSESSMENT IN OSTEOARTHRITIS
EFFICACY STUDIES AND ANTI-NERVE GROWTH FACTOR PROGRAMS:
CHARACTERISTICS AND DIFFERENCES
A. Guermazi y, M. Hellio Le Graverand z, C. Miller x, C. West k,
M. Brown x, R. Clemmer x, F. Roemer y. yBoston Univ. Sch. of Med., Boston,
MA, USA; z Pﬁzer, Tokyo, Japan; xBioClinica, Princeton, NJ, USA; k Pﬁzer,
Groton, CT, USA
Purpose: The osteoarthritis (OA) research community has long-stand-
ing experience with studies assessing therapeutic efﬁcacy, which is
commonly deﬁned as slowing of joint space narrowing (JSN). Para-
mount for longitudinal radiologic evaluation of radiographs is opti-
mized image acquisition in a reliable fashion in order to guarantee
comparability between time points. Recently nerve growth factor
inhibitors (a-NGF) have been introduced for treatment of OA symptoms,
and have shown good analgesic efﬁcacy and improvement in function
in patients with OA. However, a-NGF trials in OAwere suspended due to
concerns over accelerated rates of OA progression. Since a-NGF thera-
pies offer potential as the ﬁrst new class of analgesics in many years,
future studies assessing a-NGF compounds will include stringent eli-
gibility criteria as risk mitigation measures and will require rigorous
safety monitoring during the studies. While disease-modifying effects
are not expected with a-NGF treatment, imaging is paramount to
identify potential negative outcomes as early as possible. These imaging
ﬁndings include atrophic OA, osteonecrosis and others at screening and
especially rapidly progressive OA Type I (i.e. rapid progression of JSN
>2mm/year) and II (i.e. abnormal loss of bone or bone destruction that
